NEU

2.81%

$18.65 neuren pharmaceuticals limited

Pipeline-in-a-drug, page-13

First 13 Last

Share
Profile

Follow
geffa9

13,464 Posts.

579

01/06/24

16:36

Post #: 74119170
Share

Originally posted by Taureanbull ↑

Monopoly wharf.

Here are some very rough numbers. Working on a 66% probability of success and a value of $7.3bn per indication. That $14.5bn for the first three that have passed PH2. Assuming Angelmans is success ful. Thats coming of Reatas Valuation that Jon flagged.

I really can’t find and numbers for successful animal trials. But being a platform pipeline, with stellar animal results so far , let’s bump it up from 10% yo 20%. Because the animal models are so good and the mechanisms of action is so well understood that might even be a little low. Assuming 5 indications which is half of Jon’s less than 10 comments. Which I believe will be on the low side. After 4 positive hits last round and considering our fat bank account why wouldn’t he double down this time to 8.

But 5 X $7.3bn X 10% =$3.65bn. Or 20% =$7.3bn.

Let’s not forget to add in $4bn for NNZ2486 licensed to ACAD. If that equals 5 x royalties at peak sales. Not an exact science but it’s a start.

That totals $26.8Bn USD. Or $40.2Bn AUD.

That gives $326 per share. I wonder the CEO and BOD have very happy relaxed grins. Even if my calculations are halved we still get $163 per share.

I realise that sounds crazy and am more than happy to hear different valuations. It’s just that there has never been a drug like this before. Not that I’ve heard of,

Here is some reading that will help understand just how valuable NEU’ pipeline has become.

https://www.tandfonline.com/doi/full/10.1517/21678707.2013.752128

Expand

im bullish NEU but no chance we get anywhere near those valuations.

NEU Price at posting: $21.64 Sentiment: Hold Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

GRX

GreenX picks up prospective copper project in Germany

WGX

Westgold sets its sights on top five producer status through merger with Karora

Is oil undervalued?

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

There are more pages in this discussion • 175 more messages in this thread...

First 13 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $18.65		Change -0.540(2.81%)		Mkt cap ! $2.383B

Open	High	Low	Value	Volume
$18.98	$19.15	$18.50	$10.51M	560.3K

Buyers (Bids)

No.	Vol.	Price($)
1	1500	$18.62

Sellers (Offers)

Price($)	Vol.	No.
$18.65	1127	2

View Market Depth

No.	Vol.	Price($)
1	810	18.530
4	1225	18.510
7	2678	18.500
2	1169	18.490
1	162	18.450

Price($)	Vol.	No.
19.080	300	1
19.150	150	1
19.200	899	2
19.240	550	1
19.340	1000	1

Last trade - 16.10pm 02/08/2024 (20 minute delay)

NEU (ASX) Chart

Pipeline-in-a-drug, page-13

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

GreenX picks up prospective copper project in Germany

Westgold sets its sights on top five producer status through merger with Karora

Is oil undervalued?

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Venture to sniff out high-grade REE targets at Jupiter project, WA

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Pipeline-in-a-drug, page-13

Top Stories

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

GreenX picks up prospective copper project in Germany

Westgold sets its sights on top five producer status through merger with Karora

Is oil undervalued?

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Venture to sniff out high-grade REE targets at Jupiter project, WA

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News